QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=BF683FF4D4597F9A8DEE30D0A063FBE1;jsessionid=073828A7ABBC76B9FA3DA7CBF8431BAA;jsessionid=9BF23C244238BEC7EA65997A5A699227;jsessionid=B5682B3F2DF3DE045702F0E042CBABDB;jsessionid=0D50034C7EAC72B5E73BA01A73899487 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=BF683FF4D4597F9A8DEE30D0A063FBE1;jsessionid=073828A7ABBC76B9FA3DA7CBF8431BAA;jsessionid=9BF23C244238BEC7EA65997A5A699227;jsessionid=B5682B3F2DF3DE045702F0E042CBABDB;jsessionid=0D50034C7EAC72B5E73BA01A73899487